Reuters logo
BRIEF-Ablynx Initiates a phase III follow-up study of its first-in-class wholly-owned anti-vWF nanobody, caplacizumab, for treatment of acquired TTP
October 10, 2016 / 5:06 AM / a year ago

BRIEF-Ablynx Initiates a phase III follow-up study of its first-in-class wholly-owned anti-vWF nanobody, caplacizumab, for treatment of acquired TTP

Oct 10 (Reuters) - Ablynx NV :

* Initiates a phase III follow-up study of its first-in-class wholly-owned anti-vWF nanobody, caplacizumab, for treatment of acquired TTP

* Study duration is anticipated to be approximately three years from date last patient rolls over from HERCULES trial Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below